Alnylam Pharma (0HD2) Share Forecast & Price Target

Compare

3 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0HD2 Analyst Ratings

Strong Buy

23 Buy

5 Hold

0 Sell

Based on 28 analysts giving stock ratings to

Alnylam

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0HD2 Stock 12 Month Forecast

Average Price Target

$432.64

▼(-3.36% Downside)

Based on 28 Wall Street analysts offering 12 month price targets for Alnylam Pharma in the last 3 months. The average price target is $432.64 with a high forecast of $570.00 and a low forecast of $280.00. The average price target represents a -3.36% change from the last price of $447.68.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"237":"$237","404":"$404","571":"$571","320.5":"$320.5","487.5":"$487.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":570,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$570.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":432.64,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$432.64</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":280,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$280.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[237,320.5,404,487.5,571],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,396.655,409.98923076923074,423.3234615384615,436.6576923076923,449.99192307692306,463.32615384615383,476.6603846153846,489.9946153846154,503.32884615384614,516.6630769230769,529.9973076923077,543.3315384615385,556.6657692307692,{"y":570,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,396.655,399.4230769230769,402.19115384615384,404.95923076923077,407.72730769230765,410.4953846153846,413.2634615384615,416.03153846153845,418.7996153846154,421.5676923076923,424.3357692307692,427.1038461538461,429.87192307692305,{"y":432.64,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,396.655,387.6815384615384,378.7080769230769,369.7346153846154,360.76115384615383,351.7876923076923,342.81423076923073,333.8407692307692,324.8673076923077,315.89384615384614,306.9203846153846,297.9469230769231,288.9734615384615,{"y":280,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":263.11,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":262.52,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":276.02,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":269.22,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":254.15,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":238.55,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":276.35,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":242.733,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":267.06,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":264.3,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":303.27,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":317.45,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":396.655,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$570.00

Average Price Target$432.64

Lowest Price Target$280.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Danielle Brill

Truist Financial

―

Buy

―

Reiterated

08/27/25

Truist Financial Remains a Buy on Alnylam Pharma (ALNY)

Liisa Bayko

Evercore ISI

$280

Buy

-37.46%

Downside

Reiterated

08/22/25

Evercore ISI Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)

Dex Genotek

TR | OpenAI - 4o

$432→$479

Hold

7.00%

Upside

Reiterated

08/19/25

AI Generated ArticleAI Generated Article

Paul Matteis

Stifel Nicolaus

$441

Buy

-1.49%

Downside

Reiterated

08/14/25

Stifel Nicolaus Remains a Buy on Alnylam Pharma (ALNY)

Patrick Trucchio

H.C. Wainwright

$500→$570

Buy

27.32%

Upside

Reiterated

08/07/25

Alnylam Pharma: Strong Commercial Performance and Promising Pipeline Drive Buy Rating

Ritu Baral

TD Cowen

$482

Buy

7.67%

Upside

Reiterated

08/06/25

TD Cowen Remains a Buy on Alnylam Pharma (ALNY)

Jessica Fye

J.P. Morgan

$348→$475

Buy

6.10%

Upside

Reiterated

08/06/25

Alnylam Pharma: Strong Growth Prospects and Transition to Profitability Support Buy Rating

Mani Foroohar

Leerink Partners

$246→$343

Hold

-23.38%

Downside

Reiterated

08/06/25

Alnylam Pharma (ALNY) Gets a Hold from Leerink Partners

Andy Chen

Wolfe Research

―

Hold

―

Upgraded

08/04/25

Alnylam upgraded to Peer Perform from Underperform at Wolfe ResearchAlnylam upgraded to Peer Perform from Underperform at Wolfe Research

Leland Gershell

Oppenheimer

$490

Buy

9.45%

Upside

Upgraded

08/04/25

Alnylam upgraded to Outperform from Perform at OppenheimerAlnylam upgraded to Outperform from Perform at Oppenheimer

Eliana Merle

UBS

$403→$550

Buy

22.86%

Upside

Reiterated

08/04/25

Alnylam price target raised to $550 from $403 at UBSAlnylam price target raised to $550 from $403 at UBS

Whitney Ijem

Canaccord Genuity

$390→$415

Buy

-7.30%

Downside

Reiterated

08/01/25

Alnylam price target raised to $415 from $390 at CanaccordAlnylam price target raised to $415 from $390 at Canaccord

Martin Auster

Raymond James

$424

Buy

-5.29%

Downside

Initiated

08/01/25

Alnylam assumed with an Outperform at Raymond JamesAlnylam assumed with an Outperform at Raymond James

Greg Harrison

Scotiabank

$342→$450

Buy

0.52%

Upside

Reiterated

08/01/25

Scotiabank Sticks to Its Buy Rating for Alnylam Pharma (ALNY)

Tiago Fauth

Wells Fargo

$333→$395

Hold

-11.77%

Downside

Reiterated

08/01/25

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY) and Baxter International (NYSE: BAX)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Danielle Brill

Truist Financial

―

Buy

―

Reiterated

08/27/25

Truist Financial Remains a Buy on Alnylam Pharma (ALNY)

Liisa Bayko

Evercore ISI

$280

Buy

-37.46%

Downside

Reiterated

08/22/25

Evercore ISI Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)

Dex Genotek

TR | OpenAI - 4o

$432→$479

Hold

7.00%

Upside

Reiterated

08/19/25

AI Generated ArticleAI Generated Article

Paul Matteis

Stifel Nicolaus

$441

Buy

-1.49%

Downside

Reiterated

08/14/25

Stifel Nicolaus Remains a Buy on Alnylam Pharma (ALNY)

Patrick Trucchio

H.C. Wainwright

$500→$570

Buy

27.32%

Upside

Reiterated

08/07/25

Alnylam Pharma: Strong Commercial Performance and Promising Pipeline Drive Buy Rating

Ritu Baral

TD Cowen

$482

Buy

7.67%

Upside

Reiterated

08/06/25

TD Cowen Remains a Buy on Alnylam Pharma (ALNY)

Jessica Fye

J.P. Morgan

$348→$475

Buy

6.10%

Upside

Reiterated

08/06/25

Alnylam Pharma: Strong Growth Prospects and Transition to Profitability Support Buy Rating

Mani Foroohar

Leerink Partners

$246→$343

Hold

-23.38%

Downside

Reiterated

08/06/25

Alnylam Pharma (ALNY) Gets a Hold from Leerink Partners

Andy Chen

Wolfe Research

―

Hold

―

Upgraded

08/04/25

Alnylam upgraded to Peer Perform from Underperform at Wolfe ResearchAlnylam upgraded to Peer Perform from Underperform at Wolfe Research

Leland Gershell

Oppenheimer

$490

Buy

9.45%

Upside

Upgraded

08/04/25

Alnylam upgraded to Outperform from Perform at OppenheimerAlnylam upgraded to Outperform from Perform at Oppenheimer

Eliana Merle

UBS

$403→$550

Buy

22.86%

Upside

Reiterated

08/04/25

Alnylam price target raised to $550 from $403 at UBSAlnylam price target raised to $550 from $403 at UBS

Whitney Ijem

Canaccord Genuity

$390→$415

Buy

-7.30%

Downside

Reiterated

08/01/25

Alnylam price target raised to $415 from $390 at CanaccordAlnylam price target raised to $415 from $390 at Canaccord

Martin Auster

Raymond James

$424

Buy

-5.29%

Downside

Initiated

08/01/25

Alnylam assumed with an Outperform at Raymond JamesAlnylam assumed with an Outperform at Raymond James

Greg Harrison

Scotiabank

$342→$450

Buy

0.52%

Upside

Reiterated

08/01/25

Scotiabank Sticks to Its Buy Rating for Alnylam Pharma (ALNY)

Tiago Fauth

Wells Fargo

$333→$395

Hold

-11.77%

Downside

Reiterated

08/01/25

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY) and Baxter International (NYSE: BAX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Alnylam Pharma

1 Month

xxx

Success Rate

16/27 ratings generated profit

Average Return

+1.23%

reiterated a xxx

rating 19 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 59.26% of your transactions generating a profit, with an average return of +1.23% per trade.

3 Months

xxx

Success Rate

21/30 ratings generated profit

Average Return

+12.00%

reiterated a xxx

rating 27 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +12.00% per trade.

1 Year

Kostas BiliourisBMO Capital

Success Rate

20/22 ratings generated profit

Average Return

+42.78%

reiterated a buy rating last month

Copying Kostas Biliouris's trades and holding each position for 1 Year would result in 90.91% of your transactions generating a profit, with an average return of +42.78% per trade.

2 Years

xxx

Success Rate

22/22 ratings generated profit

Average Return

+99.31%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +99.31% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0HD2 Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0HD2 has received 40 Buy Ratings, 15 Hold Ratings, and 0 Sell Ratings. 0HD2 average Analyst price target in the past 3 months is 432.64.

Each month's total comprises the sum of three months' worth of ratings.

0HD2 Financial Forecast

0HD2 Earnings Forecast

Next quarter’s earnings estimate for 0HD2 is $0.23 with a range of -$1.10 to $2.24. The previous quarter’s EPS was -$0.51. 0HD2 beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.12% of the time in the same period. In the last calendar year 0HD2 has Outperformed its overall industry.

0HD2 Sales Forecast

Next quarter’s sales forecast for 0HD2 is $910.71M with a range of $654.00M to $1.14B. The previous quarter’s sales results were $773.69M. 0HD2 beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.23% of the time in the same period. In the last calendar year 0HD2 has Outperformed its overall industry.

0HD2 Stock Forecast FAQ

What is GB:0HD2’s average 12-month price target, according to analysts?

Based on analyst ratings, Alnylam Pharmaceuticals’s 12-month average price target is 432.64.

What is GB:0HD2’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for GB:0HD2, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Alnylam Pharmaceuticals a Buy, Sell or Hold?

Alnylam Pharmaceuticals has a consensus rating of Strong Buy, which is based on 23 buy ratings, 5 hold ratings and 0 sell ratings.

What is Alnylam Pharmaceuticals’s share price target?

The average share price target for Alnylam Pharmaceuticals is 432.64. This is based on 28 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $570.00 ,and the lowest forecast is $280.00. The average share price target represents -3.36% Decrease from the current price of $447.68.

What do analysts say about Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 28 Wall Streets Analysts.

How can I buy shares of Alnylam Pharmaceuticals?

To buy shares of GB:0HD2, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Alnylam Pharma (0HD2) Share Forecast & Price Target

0HD2 Analyst Ratings

0HD2 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Alnylam Pharma

0HD2 Analyst Recommendation Trends

0HD2 Financial Forecast

0HD2 Earnings Forecast

0HD2 Sales Forecast

0HD2 Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts